{"id":781,"date":"2026-01-20T03:20:25","date_gmt":"2026-01-20T03:20:25","guid":{"rendered":"https:\/\/bcregmed.co.uk\/?page_id=781"},"modified":"2026-01-20T05:46:56","modified_gmt":"2026-01-20T05:46:56","slug":"ace-reno-clinical-trial","status":"publish","type":"page","link":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/","title":{"rendered":"\u062a\u062c\u0631\u0628\u0629 \u0625\u064a\u0633 \u0631\u064a\u0646\u0648\u2122 \u0631\u064a\u0646\u0648 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629"},"content":{"rendered":"<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\"><div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" data-src=\"https:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-495x1024.png\" alt=\"\" class=\"wp-image-782 lazyload\" style=\"aspect-ratio:0.4834002037294971;width:296px;height:auto\"><noscript><img decoding=\"async\" width=\"495\" height=\"1024\" src=\"https:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-495x1024.png\" alt=\"\" class=\"wp-image-782\" style=\"aspect-ratio:0.4834002037294971;width:296px;height:auto\" srcset=\"http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-495x1024.png 495w, http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-145x300.png 145w, http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-768x1589.png 768w, http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-743x1536.png 743w, http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-6x12.png 6w, http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy-600x1241.png 600w, http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/ACE_Reno_product-copy.png 990w\" sizes=\"(max-width: 495px) 100vw, 495px\" \/><\/noscript><\/figure>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h3 class=\"wp-block-heading\">\u062a\u062c\u0631\u0628\u0629 \u0625\u064a\u0633 \u0631\u064a\u0646\u0648\u2122 \u0631\u064a\u0646\u0648 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Title:<\/strong>&nbsp;ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR &amp; Renal Function<\/li>\n\n\n\n<li><strong>Clinical Trial ID:<\/strong>\u00a0NCT07187713<\/li>\n\n\n\n<li><strong>Product:<\/strong>&nbsp;ACE Reno<br>(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix)<\/li>\n<\/ul>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07187713\">READ MORE<\/a><\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Background<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix technology processes tissue-derived peptides into nanometer and picometer-scale fragments to deliver regenerative potential. ACE Reno\u2122 applies this technology specifically for renal function support.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Study Purpose<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The purpose of this trial is to evaluate both the&nbsp;<strong>safety<\/strong>&nbsp;\u0648&nbsp;<strong>efficacy<\/strong>&nbsp;of ACE Reno when administered via the oral-transmucosal route in adult participants with reduced eGFR (kidney function impairment).&nbsp;<\/p>\n<\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Key Features of the Trial<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Intervention:<\/strong>&nbsp;ACE Reno, oral\/transmucosal solution, containing Pico Cell Matrix-derived peptides.<\/li>\n\n\n\n<li><strong>Primary Outcome:<\/strong>&nbsp;Change in eGFR over time (e.g., improvement or stabilisation of kidney filtration function).<\/li>\n\n\n\n<li><strong>Design:<\/strong>&nbsp;Single arm (or as specified in the registry) evaluating safety and renal function outcomes in enrolled participants.<\/li>\n\n\n\n<li><strong>Enrollment:<\/strong>&nbsp;Adult subjects with impaired renal function (reduced eGFR) meeting inclusion\/exclusion criteria specified in the registry.<\/li>\n\n\n\n<li><strong>Duration &amp; Follow-Up:<\/strong>&nbsp;As specified in the ClinicalTrials.gov record (visit schedule, assessment intervals), to monitor both renal markers and adverse events.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Why This Trial Matters<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>It represents the first clinical investigation of ACE Reno in humans targeting renal function using the Pico Cell Matrix technology.<\/li>\n\n\n\n<li>If successful, ACE Reno may offer a novel, non-invasive option for kidney support and regeneration, particularly relevant for patients with CKD or declining eGFR.<\/li>\n\n\n\n<li>Conducting this trial underscores our commitment to rigorous clinical evaluation and transparency as we advance our product pipeline toward evidence-based outcomes.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Disclosure &amp; Notes<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>This study is conducted in accordance with Good Clinical Practice (GCP) standards.<\/li>\n\n\n\n<li>The product ACE Reno is currently investigational in this clinical trial; results are not yet conclusive, and the product is not approved for the treatment of kidney disease.<\/li>\n\n\n\n<li>Participants should be informed of the potential risks and benefits as outlined in the trial informed consent form.<\/li>\n\n\n\n<li>The trial status (e.g., recruiting, active, completed) can be checked on ClinicalTrials.gov for any updates.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>ACE Reno\u2122 Clinical Trial Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix technology processes tissue-derived peptides into nanometer and picometer-scale fragments to deliver regenerative potential. ACE Reno\u2122 applies this technology specifically for renal function support. Study Purpose The purpose of this &#8230; <a title=\"\u062a\u062c\u0631\u0628\u0629 \u0625\u064a\u0633 \u0631\u064a\u0646\u0648\u2122 \u0631\u064a\u0646\u0648 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629\" class=\"read-more\" href=\"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/\" aria-label=\"Read more about ACE Reno\u2122 Clinical Trial\">\u0627\u0642\u0631\u0623 \u0627\u0644\u0645\u0632\u064a\u062f<\/a><\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"content-type":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"class_list":["post-781","page","type-page","status-publish"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"ACE Reno\u2122 Clinical Trial Title: ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR &amp; Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"google-site-verification\" content=\"KXhGAhGeneL3A_0XA0SIyua66_uwoltIj5b-9s4DpnQ\" \/>\n\t<link rel=\"canonical\" href=\"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"ar_AR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"BCRMED Global - Redefining Healing Through Regenerative Medicine\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"ACE Reno\u2122 Clinical Trial - BCRMED Global\" \/>\n\t\t<meta property=\"og:description\" content=\"ACE Reno\u2122 Clinical Trial Title: ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR &amp; Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix\" \/>\n\t\t<meta property=\"og:url\" content=\"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/\" \/>\n\t\t<meta property=\"og:image\" content=\"http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/cropped-BCRMEDLOGOx-01-01.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-01-20T03:20:25+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-01-20T05:46:56+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61574857696587\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@bcrmed\" \/>\n\t\t<meta name=\"twitter:title\" content=\"ACE Reno\u2122 Clinical Trial - BCRMED Global\" \/>\n\t\t<meta name=\"twitter:description\" content=\"ACE Reno\u2122 Clinical Trial Title: ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR &amp; Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@bcrmed\" \/>\n\t\t<meta name=\"twitter:image\" content=\"http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/cropped-BCRMEDLOGOx-01-01.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/#listItem\",\"name\":\"ACE Reno\\u2122 Clinical Trial\"}},{\"@type\":\"ListItem\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/#listItem\",\"position\":2,\"name\":\"ACE Reno\\u2122 Clinical Trial\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/#organization\",\"name\":\"British Centre for regenerative medicine\",\"description\":\"Redefining Healing Through Regenerative Medicine bcrmed, online_clinic, longevity, regerative\",\"url\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/\",\"telephone\":\"+447473922553\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"http:\\\/\\\/bcregmed.co.uk\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/cropped-BCRMEDLOGOx-01-01.png\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/#organizationLogo\",\"width\":1560,\"height\":964},\"image\":{\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61574857696587\",\"https:\\\/\\\/x.com\\\/bcrmed\",\"https:\\\/\\\/www.instagram.com\\\/bcregmed\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@tlmezero\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/86389870\\\/admin\\\/page-posts\\\/published\\\/\"]},{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/#webpage\",\"url\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/\",\"name\":\"ACE Reno\\u2122 Clinical Trial - BCRMED Global\",\"description\":\"ACE Reno\\u2122 Clinical Trial Title: ACE Reno\\u2122, Pico Cell Matrix and Its Effect on eGFR & Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\\\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix\",\"inLanguage\":\"ar\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/#website\"},\"breadcrumb\":{\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/ace-reno-clinical-trial\\\/#breadcrumblist\"},\"datePublished\":\"2026-01-20T03:20:25+00:00\",\"dateModified\":\"2026-01-20T05:46:56+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/#website\",\"url\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/\",\"name\":\"BCRMED\",\"description\":\"Redefining Healing Through Regenerative Medicine\",\"inLanguage\":\"ar\",\"publisher\":{\"@id\":\"http:\\\/\\\/bcregmed.co.uk\\\/ar\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"ACE Reno\u2122 Clinical Trial - BCRMED Global","description":"ACE Reno\u2122 Clinical Trial Title: ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR & Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix","canonical_url":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"KXhGAhGeneL3A_0XA0SIyua66_uwoltIj5b-9s4DpnQ","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"http:\/\/bcregmed.co.uk\/ar\/#listItem","position":1,"name":"Home","item":"http:\/\/bcregmed.co.uk\/ar\/","nextItem":{"@type":"ListItem","@id":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/#listItem","name":"ACE Reno\u2122 Clinical Trial"}},{"@type":"ListItem","@id":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/#listItem","position":2,"name":"ACE Reno\u2122 Clinical Trial","previousItem":{"@type":"ListItem","@id":"http:\/\/bcregmed.co.uk\/ar\/#listItem","name":"Home"}}]},{"@type":"Organization","@id":"http:\/\/bcregmed.co.uk\/ar\/#organization","name":"British Centre for regenerative medicine","description":"Redefining Healing Through Regenerative Medicine bcrmed, online_clinic, longevity, regerative","url":"http:\/\/bcregmed.co.uk\/ar\/","telephone":"+447473922553","logo":{"@type":"ImageObject","url":"http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/cropped-BCRMEDLOGOx-01-01.png","@id":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/#organizationLogo","width":1560,"height":964},"image":{"@id":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61574857696587","https:\/\/x.com\/bcrmed","https:\/\/www.instagram.com\/bcregmed\/","https:\/\/www.tiktok.com\/@tlmezero","https:\/\/www.linkedin.com\/company\/86389870\/admin\/page-posts\/published\/"]},{"@type":"WebPage","@id":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/#webpage","url":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/","name":"ACE Reno\u2122 Clinical Trial - BCRMED Global","description":"ACE Reno\u2122 Clinical Trial Title: ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR & Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix","inLanguage":"ar","isPartOf":{"@id":"http:\/\/bcregmed.co.uk\/ar\/#website"},"breadcrumb":{"@id":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/#breadcrumblist"},"datePublished":"2026-01-20T03:20:25+00:00","dateModified":"2026-01-20T05:46:56+00:00"},{"@type":"WebSite","@id":"http:\/\/bcregmed.co.uk\/ar\/#website","url":"http:\/\/bcregmed.co.uk\/ar\/","name":"BCRMED","description":"Redefining Healing Through Regenerative Medicine","inLanguage":"ar","publisher":{"@id":"http:\/\/bcregmed.co.uk\/ar\/#organization"}}]},"og:locale":"ar_AR","og:site_name":"BCRMED Global - Redefining Healing Through Regenerative Medicine","og:type":"article","og:title":"ACE Reno\u2122 Clinical Trial - BCRMED Global","og:description":"ACE Reno\u2122 Clinical Trial Title: ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR &amp; Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix","og:url":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/","og:image":"http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/cropped-BCRMEDLOGOx-01-01.png","article:published_time":"2026-01-20T03:20:25+00:00","article:modified_time":"2026-01-20T05:46:56+00:00","article:publisher":"https:\/\/www.facebook.com\/profile.php?id=61574857696587","twitter:card":"summary_large_image","twitter:site":"@bcrmed","twitter:title":"ACE Reno\u2122 Clinical Trial - BCRMED Global","twitter:description":"ACE Reno\u2122 Clinical Trial Title: ACE Reno\u2122, Pico Cell Matrix and Its Effect on eGFR &amp; Renal Function Clinical Trial ID: NCT07187713 Product: ACE Reno(oral\/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix) READ MORE Background Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix","twitter:creator":"@bcrmed","twitter:image":"http:\/\/bcregmed.co.uk\/wp-content\/uploads\/2026\/01\/cropped-BCRMEDLOGOx-01-01.png"},"aioseo_meta_data":{"post_id":"781","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-01-20 03:13:53","updated":"2026-01-20 05:50:44","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"http:\/\/bcregmed.co.uk\/ar\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tACE Reno\u2122 Clinical Trial\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"http:\/\/bcregmed.co.uk\/ar\/"},{"label":"ACE Reno\u2122 Clinical Trial","link":"http:\/\/bcregmed.co.uk\/ar\/ace-reno-clinical-trial\/"}],"_links":{"self":[{"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/pages\/781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/comments?post=781"}],"version-history":[{"count":10,"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/pages\/781\/revisions"}],"predecessor-version":[{"id":888,"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/pages\/781\/revisions\/888"}],"wp:attachment":[{"href":"http:\/\/bcregmed.co.uk\/ar\/wp-json\/wp\/v2\/media?parent=781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}